In this multicenter retrospective study, we investigated the factors associated with survival outcomes of second-line treatments for EGFR-mutant NSCLC in patients with disease progression on first- or second-generation EGFR-TKI in Taiwan. Here, EGFR is linked to non-small cell lung carcinoma.